Get the Stockscreener App
4.705
1.02%
-0.045
Arbutus Biopharma Corp stock is traded at $4.705, with a volume of 438.00K.
It is down -1.02% in the last 24 hours and up +28.11% over the past month.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
See More
Previous Close:
$4.75
Open:
$4.66
24h Volume:
438.00K
Relative Volume:
0.25
Market Cap:
$904.88M
Revenue:
$12.99M
Net Income/Loss:
$-74.39M
P/E Ratio:
-10.69
EPS:
-0.44
Net Cash Flow:
$-78.92M
1W Performance:
+0.04%
1M Performance:
+28.11%
6M Performance:
+11.95%
1Y Performance:
+35.89%
1-Day Range:
$4.66
$4.81
1-Week Range:
$4.30
$4.81
52-Week Range:
$2.705
$5.10
Arbutus Biopharma Corp Stock (ABUS) Company Profile
Name
Arbutus Biopharma Corp
Sector
Industry
Phone
604-419-3200
Address
701 VETERANS CIRCLE, WARMINSTER, PA
Compare ABUS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
4.705 | 913.54M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.37 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.63 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
726.83 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
323.11 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
294.78 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-22 | Upgrade | Jefferies | Hold → Buy |
| Feb-25-21 | Initiated | Jefferies | Hold |
| Dec-17-20 | Initiated | H.C. Wainwright | Buy |
| Jul-27-20 | Resumed | JMP Securities | Mkt Outperform |
| Jul-24-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-19-20 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-06-20 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-20-20 | Initiated | Robert W. Baird | Outperform |
| Feb-05-20 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Oct-07-19 | Reiterated | B. Riley FBR | Buy |
| Oct-04-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-16-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-15-18 | Upgrade | Wedbush | Underperform → Neutral |
| Oct-12-18 | Reiterated | Chardan Capital Markets | Buy |
| Jul-06-18 | Downgrade | B. Riley FBR, Inc. | Buy → Neutral |
| Mar-19-18 | Resumed | Chardan Capital Markets | Buy |
| Mar-19-18 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Apr-04-17 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-01-17 | Reiterated | Wedbush | Outperform |
| Dec-13-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-30-16 | Upgrade | Chardan Capital Markets | Neutral → Buy |
View All
Arbutus Biopharma Corp Stock (ABUS) Latest News
Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation - Investing.com
Here's Arbutus Biopharma's share of $950M Moderna settlement - The Business Journals
Arbutus Biopharma (NASDAQ:ABUS) Sees Strong Trading VolumeWhat's Next? - MarketBeat
Arbutus Biopharma (ABUS) Reaches Settlement with Moderna Over Pa - GuruFocus
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal By Investing.com - Investing.com Canada
MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS - Finviz
Chardan reiterates Arbutus Biopharma stock rating on Moderna deal - Investing.com
ABUS: Key Developments and Market Impact - GuruFocus
Moderna's $950 Million Settlement Clears Legal Overhang, Stock Soars - Benzinga
Moderna to pay about US$1 bil to settle Arbutus litigation - The Edge Malaysia
Genevant and Arbutus agree $2.25 billion global settlement with Moderna - The Pharma Letter
Moderna to Pay About $1 Billion to Settle Arbutus Litigation - Bloomberg.com
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket - Benzinga
Moderna Shares Rise 16% After Company Enters Settlement Agreement With Arbutus Biopharma, Genevant Sciences - Bitget
Moderna to pay Genevant Sciences and Arbutus Biopharma up to $2.25 billion in global patent settlement - PharmaLive
Arbutus Biopharma (ABUS) and Genevant Reach $2.25 Billion Settle - GuruFocus
Arbutus Biopharma Reaches Transformative Global Settlement With Moderna - TipRanks
Roivant, Arbutus Biopharma stocks surges on $2.25B Moderna settlement - Investing.com
Roivant's Genevant and Arbutus reach $2.25 billion settlement with Moderna - StreetInsider
Arbutus Biopharma (Nasdaq: ABUS) details $2.25B Moderna patent settlement - Stock Titan
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna - GlobeNewswire
Moderna Royalty Loss Raises Covid-Shot Trial Stakes (Correct) - Bloomberg Law News
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
Key patent ruling boosts Arbutus Biopharma (NASDAQ: ABUS) in Moderna LNP case - Stock Titan
Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna - Intellectia AI
Delaware Court Narrows Moderna’s Invalidity Defenses Ahead of Arbutus LNP Patent Trial - IPWatchdog.com
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Two Seas Capital reports 6.5% Arbutus Biopharma (ABUS) ownership - Stock Titan
What insider trading reveals about Arbutus Biopharma Corporation stockMarket Risk Summary & Fast Entry and Exit Trade Plans - mfd.ru
Will Arbutus Biopharma Corporation stock remain a Wall Street favorite2025 Top Decliners & Comprehensive Market Scan Insights - mfd.ru
Moving Averages: How does Arbutus Biopharma Corporation correlate with NasdaqWeekly Investment Report & Smart Investment Allocation Insights - baoquankhu1.vn
Court narrows but sustains Arbutus (NASDAQ: ABUS) patent claims in Moderna COVID-19 vaccine fight - Stock Titan
PATENT—D. Del.: Most COVID-19... - VitalLaw.com
Moderna Again Fails to Shift Most Covid-Shot Patent Costs to US - Bloomberg Law News
Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 6.8%What's Next? - MarketBeat
Patent Ruling Update Affects Arbutus Biopharma (ABUS) in Legal B - GuruFocus
Arbutus Biopharma (ABUS) Rises on Patent Dispute Jury Trial Deci - GuruFocus
Arbutus Biopharma (ABUS) Shares Surge Amid Market Fluctuations - GuruFocus
Arbutus Biopharma (ABUS) Patent Dispute Over COVID-19 Vaccine De - GuruFocus
Arbutus jumps on ruling in patent dispute with Moderna (ABUS:NASDAQ) - Seeking Alpha
Traders Buy Large Volume of Call Options on Arbutus Biopharma (NASDAQ:ABUS) - MarketBeat
Aug Drivers: Can Arbutus Biopharma Corporation ride the EV waveQuarterly Investment Review & Consistent Return Strategy Ideas - baoquankhu1.vn
Arbutus Biopharma (NASDAQ:ABUS) Stock Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat
Aug Closing: Should I buy Arbutus Biopharma Corporation stock nowJuly 2025 Volume & Weekly High Momentum Picks - baoquankhu1.vn
Arbutus Biopharma (ABUS) Patent Invalidated by European Patent O - GuruFocus
Arbutus Biopharma (ABUS) Faces Patent Revocation in Europe - GuruFocus
ABUS Stock Tumbles on European Patent Revocation - StocksToTrade
Arbutus Biopharma (ABUS) Shares Drop Amid Patent Revocation - GuruFocus
Market Dynamics Cause Shifts for Arbutus Biopharma - StocksToTrade
Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash - Intellectia AI
Arbutus Biopharma (NASDAQ:ABUS) Shares Gap DownHere's Why - MarketBeat
Arbutus Biopharma Corp Stock (ABUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):